Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has Editas Medicine's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EDIT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: EDIT's weekly volatility (10%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: EDIT exceeded the US Biotechs industry which returned 24.5% over the past year.
Return vs Market: EDIT underperformed the US Market which returned 49.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Editas Medicine's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWe're Not Very Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate
1 month ago | Simply Wall StThe Editas Medicine (NASDAQ:EDIT) Share Price Is Up 104% And Shareholders Are Boasting About It
2 months ago | Simply Wall StChairman James Mullen Just Bought 250% More Shares In Editas Medicine, Inc. (NASDAQ:EDIT)
Is Editas Medicine undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EDIT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EDIT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EDIT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: EDIT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EDIT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EDIT is overvalued based on its PB Ratio (3.6x) compared to the US Biotechs industry average (3.5x).
How is Editas Medicine forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EDIT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EDIT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EDIT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EDIT's revenue (56.8% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: EDIT's revenue (56.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EDIT is forecast to be unprofitable in 3 years.
How has Editas Medicine performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EDIT is currently unprofitable.
Growing Profit Margin: EDIT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EDIT is unprofitable, and losses have increased over the past 5 years at a rate of 7.4% per year.
Accelerating Growth: Unable to compare EDIT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EDIT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.6%).
Return on Equity
High ROE: EDIT has a negative Return on Equity (-21.16%), as it is currently unprofitable.
How is Editas Medicine's financial position?
Financial Position Analysis
Short Term Liabilities: EDIT's short term assets ($632.3M) exceed its short term liabilities ($64.0M).
Long Term Liabilities: EDIT's short term assets ($632.3M) exceed its long term liabilities ($78.3M).
Debt to Equity History and Analysis
Debt Level: EDIT is debt free.
Reducing Debt: EDIT had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EDIT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: EDIT has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 39.4% each year.
What is Editas Medicine current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EDIT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EDIT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EDIT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EDIT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EDIT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jim Mullen (61 yo)
Mr. James C. Mullen, also known as Jim, serves as Chief Executive Officer and President of Editas Medicine, Inc. since February 15, 2021. He serves as a Member of Strategic Advisory Board at Longwood Fund....
Experienced Management: EDIT's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: EDIT's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: EDIT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.5%.
Editas Medicine, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Editas Medicine, Inc.
- Ticker: EDIT
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.310b
- Shares outstanding: 67.72m
- Website: https://www.editasmedicine.com
Number of Employees
- Editas Medicine, Inc.
- 11 Hurley Street
- United States
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platfor...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/10 03:29|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.